Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Shirai

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Journal of Thoracic Disease|September 16, 2021
Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitorsYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
BMJ Case Reports|August 21, 2021
Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanomaYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
Journal for Immunotherapy of Cancer|February 14, 2018
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy aloneMuhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai
Journal for Immunotherapy of Cancer|July 4, 2018
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanomaMuhammad Zubair Afzal, Rima R Mercado, Keisuke Shirai
Cancer Medicine|August 29, 2014
Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgeryKarim Tazi, Amanda Hathaway, Cody Chiuzan, et al.
Hematological Oncology|September 3, 2010
Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literatureMunira Shabbir, John Lucas, John Lazarchick, et al.
Lung Cancer Management|October 25, 2019
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitorsMuhammad Z Afzal, Konstantin Dragnev, Tayyaba Sarwar, et al.
BMJ Case Reports|July 14, 2023
Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegibJonathan Pirruccello, Muhammad Zubair Afzal, Mariana Voudouri, et al.
Melanoma Research|October 13, 2023
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitorsYuanzhen Cao, Muhammad Zubair Afzal, Edward J Gutmann, et al.
Case Reports in Oncology|February 29, 2020
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case ReportSivraj Muralikrishnan, Lara K Ronan, Shodeinde Coker, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Journal of Thoracic Disease|September 16, 2021
Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitorsYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
BMJ Case Reports|August 21, 2021
Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanomaYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
Journal for Immunotherapy of Cancer|February 14, 2018
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy aloneMuhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai
Journal for Immunotherapy of Cancer|July 4, 2018
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanomaMuhammad Zubair Afzal, Rima R Mercado, Keisuke Shirai
Cancer Medicine|August 29, 2014
Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgeryKarim Tazi, Amanda Hathaway, Cody Chiuzan, et al.
Hematological Oncology|September 3, 2010
Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literatureMunira Shabbir, John Lucas, John Lazarchick, et al.
Lung Cancer Management|October 25, 2019
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitorsMuhammad Z Afzal, Konstantin Dragnev, Tayyaba Sarwar, et al.
BMJ Case Reports|July 14, 2023
Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegibJonathan Pirruccello, Muhammad Zubair Afzal, Mariana Voudouri, et al.
Melanoma Research|October 13, 2023
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitorsYuanzhen Cao, Muhammad Zubair Afzal, Edward J Gutmann, et al.
Case Reports in Oncology|February 29, 2020
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case ReportSivraj Muralikrishnan, Lara K Ronan, Shodeinde Coker, et al.
Pageof 9